NA
ALLO icon

Nordwand Advisors’s Allogene Therapeutics ALLO Stock Holding History

Nordwand Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$2.33K – 144
2024
Q2 		$2.33K Buy
+1,000
New +$2.95K ﹤0.01% 142
2023
Q1 		– Sell
-9,528
Closed -$59.9K – 128
2022
Q4 		$59.9K Buy
+9,528
New +$88.2K 0.01% 62

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors's ALLO Position: Q3 2024 in Review

Nordwand Advisors sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 1,000 shares — an estimated $2.33K sold.

Nordwand Advisors first reported a position in ALLO in Q4 2022 and held it in 2 quarters. The position peaked at $59.9K in Q4 2022. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • Nordwand Advisors reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Nordwand Advisors sold 1,000 Allogene Therapeutics shares in Q3 2024, an estimated $2.33K.
  • Nordwand Advisors first reported a position in Allogene Therapeutics in Q4 2022 and held it in 2 quarters.
  • Nordwand Advisors's Allogene Therapeutics position peaked at $59.9K in Q4 2022.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on Nordwand Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.